ArticleFrontiers in medicine2025
P2RY13+ dendritic cells correlate with enhanced antigen presentation and lymphocyte activation in lung adenocarcinoma.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- P2RY13-Negative Tumor-Associated Macrophages Promote NETosis and Are Associated with Poor Prognosis Across Multiple Cancers.Cancers · 2026Article
- LRP1 Activation Promotes Metabolic Reprogramming and Mrc1 Expression to Attenuate LPS-Induced Cognitive Deficits: An Integrated Omics Analysis.CNS neuroscience & therapeutics · 2026Article
- Acylation modification mediated post-translational modifications learning signature reveals ZDHHC18 promotes progression of lung adenocarcinoma by attenuating immunocyte activation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although P2RY13 has been implicated in immune regulation and prognosis in lung adenocarcinoma (LUAD), its specific cellular expression and functional mechanisms within the tumor microenvironment (TME) remain poorly understood. Methods: We integrated transcriptomic and clinical data from TCGA and GEO (GSE68465 and GSE31210), performed differential gene expression and functional enrichment analyses, and employed multiple algorithms including CIBERSORT, MCP-counter, quanTIseq, TIMER, and ESTIMATE to evaluate immune infiltration. Single-cell RNA sequencing data (GSE131907) was analyzed using Seurat to identify cell-type-specific expression, while CellChat was used to infer intercellular communication. Pathway activities were assessed with eight scoring methods (AUCell, UCell, AddModuleScore, GSVA, JASMINE, singscore, ssGSEA, viper) using MSigDB gene sets. Results: Our results demonstrated that P2RY13 was significantly downregulated in LUAD and predicted poor prognosis independently. It correlated positively with immune infiltration, particularly T cell markers. Single-cell analysis revealed specific enrichment in dendritic cells (DCs), with P2RY13(+) DCs more prevalent in normal tissues and exhibiting enhanced activity in antigen presentation and T cell activation. Conclusion: P2RY13 is an independent prognostic biomarker in LUAD, linked to an immunologically active TME. Its specific expression in dendritic cells enhances antigen presentation and T cell activation, underscoring its role in promoting anti-tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.